Fexinidazole
- TRADE NAME: Fexinidazole (Sanofi)
- INDICATIONS: Treatment of both first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis due to Trypanosoma brucei gambiense.
- SYNONYM: Fexinidazole Winthrop
- CLASS: Antimicrobial, Antiprotozoal
FDA APPROVAL DATE: 07/16/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Adefovir, Bupropion, Carbamazepine, Cefaclor, Clarithromycin, Diazepam, Dofetilide, Duloxetine, Efavirenz, Erythromycin, Fluconazole, Furosemide, Itraconazole, Lansoprazole, Lovastatin, Mephenytoin, Metformin, Midazolam, Nisoldipine, Phenytoin, Rifampin, Saquinavir, Simvastatin, St John's Wort, Tacrine, Theophylline, Tizanidine, Voriconazole
Insufficient to evaluate for a drug-associated risk of major birth defects or miscarriage.
Avoid concomitant use of herbal medicines and supplements
during treatment with fexinidazole.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
Page last updated 01/16/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric